Document is current
Any future updates will be listed below
-
Authors
Amiel, Stephanie A. http://orcid.org/0000-0003-2686-5531
Potts, Laura
Goldsmith, Kimberley
Jacob, Peter
Smith, Emma L.
Gonder-Frederick, Linda
Heller, Simon http://orcid.org/0000-0002-2425-9565
Toschi, Elena http://orcid.org/0000-0003-4077-1160
Brooks, Augustin
Kariyawasam, Dulmini
Choudhary, Pratik
Stadler, Marietta
Rogers, Helen
Kendall, Mike http://orcid.org/0000-0002-4829-5560
Sevdalis, Nick
Bakolis, Ioannis
de Zoysa, Nicole
- License Information
-
More Information
Article History
Received: 25 November 2021
Accepted: 18 March 2022
First Online: 28 April 2022
Competing interests
: S.A.A. has served on Advisory Boards for Novo Nordisk and Medtronic and has spoken at educational meetings supported by NovoNordisk and Sanofi in the past year and is a co-investigator on the EU IMI HypoRESOLVE programme. P.C. has received personal fees from Abbott, Dexcom. Insulet, Medtronic, Novo Nordisk, Lilly and Sanofi. S.H. has served on Advisory Boards and Consulted with Eli Lilly, NovoNordisk, Zealand Pharma and served on speaker panels for NovoNordisk. He is a co-investigator on the EU IMI HypoRESOLVE programme. E.T. is a consultant to Medtronic. A.B. declares that he has received honoraria from Astra Zeneca and Sanofi for speaking at educational events and sponsorship from Lilly and Janssen to attend conferences. L.G.F. is on the Advisory Group for the EU IMI HypoRESOLVE programme. She is also the General Manager of HFS-Global LLC, a business developed in partnership with the University of Virginia to license use of the HFS-II to for-profit entities. No licensing fees were charged for the use of HFS-II in this study. N.S. is the director of the London Safety and Training Solutions Ltd, which offers training in patient safety, implementation solutions and human factors to health care organisations and the pharmaceutical industry. The other authors have no disclosures.
